Ken Griffin’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Ken Griffin’s Portfolio NVLN Stock Details NVLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-119,560	Closed	-$87K	–	10222
2019 Q3	$87K	Buy	119,560 +27,723	+30%	+$20.1K	﹤0.01%	8546
2019 Q2	$72K	Buy	91,837 +31,150	+51%	+$34.7K	﹤0.01%	8630
2019 Q1	$75K	Buy	+60,687	New	+$69.1K	﹤0.01%	8658
2018 Q1	–	Sell	-19,655	Closed	-$61K	–	9074
2017 Q4	$61K	Buy	+19,655	New	+$94.5K	﹤0.01%	7572

Other funds holding NVLN

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

FSA

Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return

Ken Griffin's NVLN Position: Q4 2019 in Review

Ken Griffin sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q4 2019, closing a stake of 119,560 shares — an estimated $87K sold.

Ken Griffin first reported a position in NVLN in Q4 2017 and held it in 4 quarters. The position peaked at $87K in Q3 2019. 7 funds tracked by Wall St. Rank hold NVLN as of Q4 2019.

Ken Griffin reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q4 2019 after selling out during the quarter.
Ken Griffin sold 119,560 Novelion Therapeutics Inc. Common Shares shares in Q4 2019, an estimated $87K.
Ken Griffin first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2017 and held it in 4 quarters.
Ken Griffin's Novelion Therapeutics Inc. Common Shares position peaked at $87K in Q3 2019.
7 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q4 2019.

Based on Citadel Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.